A study found that up to 33.1% of adults eligible for GLP-1 receptor agonist treatment were excluded from clinical trials due to medical and psychiatric conditions. Conditions such as major depressive disorder, uncontrolled hypertension, and liver disease were common exclusion criteria. The researchers emphasized the importance of screening for these conditions before prescribing these medications, especially in populations excluded from clinical trials. They also called for more real-world evidence to study the safety and effectiveness of these drugs in underrepresented populations. The study had limitations such as self-reported medical conditions and the inability to measure all exclusion criteria accurately.
Source link
Many people remain excluded from GLP-1 clinical trials for weight loss
